Drugs / VLA1701
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03576183 Comparator | Jun 2018 | diarrheal disease, escherichia coli infection | Valneva Austria GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VLA-1701 | “We sought to confirm the ability of the LSN03 strain to induce moderate-to-severe diarrhea in a healthy American adult population, as well as the impact of immunization with an...” PMID 38674674 ↗ Apr 2024 |
| Modality | Vaccine | “investigational oral vaccine against LT-ETEC” NCT03576183 ↗ |
| Route | Oral | “The vaccine is administered orally” NCT03576183 ↗ |